MK-677 (Ibutamoren) Dosage Guide: Oral GH Secretagogue, Half-Life & Research Protocol

MK-677 research dosing guide: oral GH secretagogue mechanism, GH pulse data, dose range (10–25 mg/day), half-life timing, and half-life calculator for protocol optimization.

TL;DR

• MK-677 (Ibutamoren) is an oral ghrelin mimetic and growth hormone secretagogue (GHS) — not a peptide, but typically classified alongside peptide research compounds
• Half-life of approximately 24 hours enables once-daily oral dosing; no reconstitution required
• Typical research doses range from 10 mg/day (low/initiation) to 25 mg/day (full dose); often dosed at night before sleep
• Significantly elevates both GH pulse amplitude and IGF-1 levels within days of initiation
• Use the Dosage Calculator for MK-677 tracking →

⚠️ Disclaimer: This article is intended for educational and research purposes only. MK-677 is not approved by the FDA for human therapeutic use. It is classified as a research chemical and is not intended for human consumption. All information presented here is drawn from published preclinical and clinical research. Nothing in this article constitutes medical advice. Consult a licensed healthcare professional before use.

MK-677, also known by its INN name Ibutamoren, occupies an unusual position in the research peptide world. It is not, strictly speaking, a peptide — it is a small-molecule non-peptide ghrelin receptor agonist. However, because of its functional overlap with the injectable growth hormone secretagogue (GHS) peptides like Ipamorelin and Hexarelin, and its widespread use in growth hormone axis research, it is almost universally discussed alongside peptide compounds in research contexts. Its oral bioavailability and once-daily dosing make it a practically distinct research tool compared to its injectable GHS counterparts.

First developed by Merck Research Laboratories in the 1990s, MK-677 reached Phase 2 clinical trials for several indications including hip fracture recovery, muscle wasting in the elderly, and growth hormone deficiency. While Merck ultimately discontinued development, the clinical trial data generated during that period provides a relatively robust evidence base that distinguishes MK-677 from many less-studied research compounds. This guide covers the mechanism, research dosing, IGF-1 effects, and a direct comparison with injectable GH secretagogue peptides.

What Is MK-677?

MK-677 (chemical name: (R)-1'-(2-methylalanyl-O-benzyl-D-seryl)-1-(methylsulfonyl)-1,2-dihydrospiro[indole-3,4'-piperidine]) is a spiropiperidine compound that acts as a selective, orally active agonist of the ghrelin receptor (GHSR-1a — Growth Hormone Secretagogue Receptor type 1a). Its molecular weight is 624.77 Da, which is large for a small molecule but within the oral bioavailability range given its specific physicochemical properties.

The key distinction between MK-677 and peptide-based GHS compounds is oral bioavailability. Peptides like Ipamorelin and Hexarelin are degraded in the gastrointestinal tract and must be administered by injection to be biologically active. MK-677 is acid-stable, resists first-pass metabolism effectively enough to achieve clinically relevant plasma concentrations after oral ingestion, and does not require any reconstitution or injection equipment. This makes it fundamentally more accessible from a research logistics standpoint.

MK-677 is not a hormone itself and does not directly introduce GH or IGF-1 into the system. Instead, it stimulates the pituitary gland's own GH release mechanisms — meaning the GH pulses it induces are physiologically regulated (to a degree) and maintain the pulsatile pattern that is characteristic of natural GH secretion. This is a significant pharmacological advantage over direct exogenous GH administration, where the natural pulsatility is lost.

Mechanism of Action

MK-677 acts as a potent, selective agonist of GHSR-1a — the ghrelin receptor — which is expressed primarily in the pituitary gland, hypothalamus, and throughout the gut, heart, and peripheral tissues. Ghrelin, the endogenous ligand for GHSR-1a, is a 28-amino-acid peptide primarily secreted by the stomach in response to fasting. Its stimulation of GHSR-1a in the pituitary triggers GH secretion; MK-677 mimics this effect with high receptor affinity and prolonged duration.

Pulsatile GH release is preserved with MK-677, unlike exogenous GH administration. GH pulses occur multiple times per day in normal physiology, with the largest pulse occurring during deep sleep (slow-wave sleep). MK-677 amplifies these pulses rather than replacing them with a continuous, non-pulsatile level. In a key clinical study published in the Journal of Clinical Endocrinology and Metabolism, 25 mg/day MK-677 increased mean 24-hour GH pulse amplitude by 3.2-fold compared to baseline while increasing the number of GH pulses by approximately 1.6-fold.

IGF-1 elevation is the most commonly measured downstream biomarker of MK-677's activity. Hepatic IGF-1 production is stimulated by GH acting on hepatic GH receptors, and IGF-1 levels are a more stable, easier-to-measure indicator of GH axis activity than the fluctuating GH pulses themselves. Research consistently shows that MK-677 at 25 mg/day elevates serum IGF-1 by 60–80% above baseline within 2–4 weeks of initiation, with levels stabilizing at this elevated plateau during continued use.

Ghrelin-receptor-mediated appetite stimulation is an on-target effect that is relevant to research design. Because ghrelin is also known as the "hunger hormone," MK-677's agonism of GHSR-1a produces a consistent increase in appetite — typically rated as noticeable but not overwhelming at research doses. This is a mechanistically expected effect that distinguishes MK-677 from more GH-selective peptides like Ipamorelin, which was specifically engineered to minimize appetite and ACTH/cortisol stimulation.

Research Dosing Patterns

MK-677 research dosing has been reasonably well characterized across multiple clinical trials and published case series. The compound does not require dose escalation in the same graduated fashion as GLP-1 agonists — it can generally be started at the target research dose without titration.

Low dose (10 mg/day): Some researchers begin with 10 mg/day to assess individual response and minimize the appetite stimulation and water retention that are commonly reported at higher doses. A Merck trial in elderly subjects used 10 mg/day and still demonstrated significant IGF-1 elevation (+30–40% above baseline), suggesting meaningful GH axis activity even at this conservative dose.

Standard research dose (25 mg/day): The 25 mg/day dose has been used in the majority of published clinical research and consistently produces 60–80% IGF-1 elevation with the most favorable efficacy-to-side-effect balance. This is typically considered the full research dose.

Timing: Because MK-677 amplifies the natural nocturnal GH pulse that accompanies deep sleep, most research protocols specify dosing 30–60 minutes before bedtime. This aligns the peak plasma concentration of MK-677 with the period of maximum pituitary GH sensitivity. Taking MK-677 in the morning is not incorrect, but evening dosing is generally preferred for maximizing GH axis activation.

Duration: Unlike most peptides that are cycled in short bursts, MK-677's IGF-1-elevating effect appears to be sustained with continued use. Some published research protocols ran 12 months or longer without evidence of desensitization at the GHSR-1a level. However, many researcher-designed protocols cycle MK-677 (e.g., 12 weeks on, 4–6 weeks off) to manage potential insulin sensitivity effects associated with chronic GH elevation.

IGF-1 Effects

IGF-1 (Insulin-like Growth Factor 1, also called somatomedin C) is the primary anabolic mediator downstream of GH signaling. GH stimulates hepatic IGF-1 production, and IGF-1 is responsible for most of GH's anabolic effects including protein synthesis promotion, cellular proliferation, and anti-catabolic activity in muscle tissue. In research contexts, serum IGF-1 level is the most reliable proxy for assessing GH axis activity.

In a landmark study by Chapman et al. (1996) published in the Journal of Clinical Endocrinology and Metabolism, 25 mg/day MK-677 in healthy older adults produced a mean IGF-1 increase of 79.3% above baseline after 2 weeks, with sustained elevation throughout the 12-month study period. Fat-free mass increased by 1.6 kg compared to placebo over this period, consistent with the anabolic effect of elevated IGF-1. Serum GH levels (measured over 24-hour pulsatile sampling) increased by 97% in pulse amplitude.

Age matters significantly in this equation: MK-677 produces larger IGF-1 responses in older subjects whose baseline GH axis activity is diminished, compared to young subjects who already have near-optimal GH secretion. This has implications for research design — a subject with naturally high IGF-1 levels may show a more modest response than the clinical trial literature would suggest.

IGF-1 reference ranges for healthy adults are generally considered to be 100–300 ng/mL, with significant variation by age. MK-677 at 25 mg/day typically elevates IGF-1 from a baseline in the lower portion of this range to values in the upper-normal to slightly supraphysiological range. Monitoring IGF-1 levels periodically during research protocols allows for assessment of response and dose appropriateness.

Oral vs. Injectable GH Secretagogues

The practical choice between MK-677 and injectable GH peptides involves tradeoffs across several dimensions. The table below compares MK-677 with the three most commonly researched injectable GHS peptides.

Ipamorelin is the most commonly paired injectable GHS peptide — it is highly selective for the ghrelin receptor with minimal off-target activity on cortisol, ACTH, or prolactin axes. Its short half-life means it must be injected 2–3 times daily, but each injection produces a clean, sharp GH pulse. CJC-1295 with DAC (Drug Affinity Complex) works via the complementary GHRH (growth hormone releasing hormone) receptor pathway, and when combined with Ipamorelin in research creates synergistic GH pulse amplitude amplification. MK-677 essentially provides a sustained version of the GHSR-1a agonism that Ipamorelin provides acutely, but without injection burden.

For researchers comparing options, MK-677 offers sustained 24-hour GH axis elevation through a single daily oral dose — but produces more appetite stimulation and water retention than selective injectable options. The injectable GHS peptides offer more precise control over GH pulse timing and generally fewer systemic side effects, but require injection equipment and multiple daily administrations.

Side Effects in Research

MK-677's side effect profile in clinical research is generally manageable and reversible upon discontinuation, but several effects are common enough to merit explicit discussion in research design.

Water retention is the most universally reported effect, caused by the GH-mediated increase in water and sodium reabsorption. This is typically most prominent in the first 2–4 weeks of use before partially attenuating. Edema in the extremities (particularly ankles and wrists) can be meaningful at higher doses.

Appetite increase is an on-target, mechanism-driven effect via ghrelin receptor activation. Most research subjects report meaningful increases in hunger, particularly in the first 2–4 weeks. This is dose-dependent — the effect is generally more manageable at 10 mg/day than 25 mg/day.

Potential insulin resistance at higher doses: Chronic elevation of GH (even via the pulsatile MK-677 mechanism) can produce physiological insulin resistance through GH's counter-regulatory effects on insulin signaling. Published clinical data from 12-month MK-677 studies showed modest increases in fasting blood glucose and insulin in a subset of subjects. This effect is more clinically relevant in subjects who already have metabolic syndrome or pre-diabetic glucose dysregulation.

Cortisol and prolactin: Unlike some older GHS compounds (e.g., GHRP-6), MK-677 shows minimal stimulation of cortisol or prolactin at research doses — a pharmacological advantage that makes it cleaner for extended research use.

Why No Reconstitution Calculator Is Needed

MK-677 is supplied as an oral capsule (typically 10 mg or 25 mg per capsule) or as a pre-dissolved oral liquid (typically 25 mg/mL). Neither format requires any reconstitution, making the reconstitution calculator irrelevant for this compound.

However, the dosage calculator remains useful for research logging, dose adjustment, and tracking cumulative intake across a multi-week research protocol. It is also helpful for documenting dose changes between the 10 mg initiation phase and 25 mg full dose, and for maintaining organized research records.

Open the Dosage Calculator for MK-677 →

See the full MK-677 database entry →

Conclusion

MK-677 (Ibutamoren) represents a practically unique research tool — the only orally bioavailable compound that meaningfully activates the growth hormone secretagogue receptor for sustained GH pulse amplification. Its once-daily oral dosing, 24-hour half-life, and well-documented IGF-1 elevation profile (60–80% above baseline at 25 mg/day) make it a compelling research compound for GH axis studies, particularly in aging models where baseline GH secretion is reduced.

While its appetite-stimulating and water retention effects require consideration in research design, the compound's lack of injectable administration requirements and its comparatively deep clinical evidence base make it accessible to a wider range of research contexts than the injectable GHS peptides. The dosage calculator is the most relevant tool for MK-677 research tracking given the absence of any reconstitution requirement.

This content is intended for research and educational purposes only. MK-677 is not approved for human therapeutic use. All research use should comply with applicable regulations and institutional guidelines.

Frequently Asked Questions About MK-677 (Ibutamoren)

Q: Is MK-677 actually a peptide? A: No — MK-677 (Ibutamoren) is technically a small-molecule non-peptide compound, specifically a spiropiperidine ghrelin receptor agonist with a molecular weight of 624.77 Da. It is classified alongside peptide research compounds because it targets the same GHSR-1a (ghrelin receptor) that injectable GH secretagogue peptides like Ipamorelin and Hexarelin activate, and it produces similar downstream effects on GH pulse amplitude and IGF-1 levels. Its key practical distinction from peptides is oral bioavailability — it survives GI digestion, while true peptide GHS compounds require injection.

Q: How does MK-677 work as a growth hormone secretagogue? A: MK-677 is a potent, selective agonist of GHSR-1a — the ghrelin receptor expressed in the pituitary and hypothalamus. By mimicking the endogenous hunger hormone ghrelin, it stimulates the pituitary gland to amplify its own GH release pulses rather than introducing exogenous GH. A clinical study published in the Journal of Clinical Endocrinology and Metabolism found 25 mg/day MK-677 increased mean 24-hour GH pulse amplitude by 3.2-fold and GH pulse number by approximately 1.6-fold, while preserving the natural pulsatile pattern of GH secretion.

Q: What is the typical MK-677 research dose? A: The standard research dose established in published clinical trials is 25 mg/day taken orally, typically 30–60 minutes before sleep to align peak plasma concentration with the natural nocturnal GH pulse. A lower initiation dose of 10 mg/day is used by some researchers to assess individual response and manage the appetite stimulation and water retention that are most pronounced at the full dose. A Merck clinical trial using 10 mg/day in elderly subjects still demonstrated significant IGF-1 elevation of 30–40% above baseline.

Q: Does MK-677 increase IGF-1 levels? A: Yes — MK-677 at 25 mg/day consistently elevates serum IGF-1 by 60–80% above baseline within 2–4 weeks of initiation, with sustained elevation throughout continued use. A landmark Chapman et al. (1996) study in healthy older adults found a mean 79.3% IGF-1 increase after 2 weeks, sustained over a 12-month period, accompanied by 1.6 kg of increased fat-free mass versus placebo. IGF-1 is the most reliable and stable biomarker for assessing GH axis response to MK-677.

Q: How does MK-677 compare to injectable GH peptides like CJC-1295? A: MK-677 and CJC-1295 work through different receptors — MK-677 targets GHSR-1a (ghrelin receptor), while CJC-1295 with DAC targets the GHRH receptor (growth hormone releasing hormone receptor). CJC-1295 DAC has an ~8-day half-life and is dosed once weekly, producing sustained IGF-1 elevation of about 40–60%; MK-677 at 25 mg/day produces 60–80% IGF-1 elevation through once-daily oral dosing. MK-677 causes more appetite stimulation due to ghrelin receptor agonism, while CJC-1295 has minimal appetite effect. The two compounds are often combined in research for synergistic GH axis activation.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions